Skip to content

European Medicine’s Agency – Reflection paper on the use of artificial intelligence in the lifecycle of medicines

Date: September 25, 2023

The EMA has opened a public consultation on a reflection paper presenting views on artificial intelligence and machine learning at any step of the lifecycle of human and veterinary medicines, from drug discovery to the post-authorisation setting.

All interested stakeholders are invited to comment on the draft reflection paper and to identify opportunities and risks of AI in the field of medicines – deadline: 31 December 2023

The topic will be further discussed during a joint HMA/EMA workshop scheduled for 20-21 November 2023.

The feedback from stakeholders will be analysed and considered for the finalisation of the reflection paper and future development of guidance as relevant.

Find out more here.

 


 

Explore More News

AI model trained on de-identified data from 57 million people

Researchers at UCL have trained an AI model using de-identified data from 57 million . . .

Read More

ACDM Regulatory Considerations DMEG Update: ICH E6 (R3) GCP Final Publication Released

The final publication of ICH E6 (R3) Good Clinical Practice (GCP) General Principles and . . .

Read More

ICH E6(R3) Guideline reaches Step 4 of the ICH Process

ICH E6(R3) reaches Step 4 of the ICH Process on 6th January 2025. The guideline . . .

Read More

U.S. Food & Drug Administration: Draft Guidance for Industry and Other Interested Parties

The U.S. Food and Drug Administration has issued its first guidance on the use of . . .

Read More

ACDM DMEG News: Regulatory Updates and Forthcoming Challenges for 2025

As 2024 draws to a close, the Regulatory Considerations Data Management Expert Group . . .

Read More

Audit Trail Review DMEG Update – New Guide

The Audit Trail Review (ATR) DMEG has been hard at work putting the finishing touches on a . . .

Read More

Risk Based Quality Management DMEG Update – Recent Discussions

This year our focus has switched away from generalised RBQM to applying risk-based . . .

Read More

Regulatory Considerations DMEG Update – September 2024

The Regulatory Considerations DMEG are waiting for the release of ICH GCP E6 (R3) Annex 1 . . .

Read More

Digital Data Flow (DDF) integration through the lens of electronic Patient-Reported Outcomes (ePRO)

This article has been submitted by Leeni Joshua of ICON plc Introduction: Digital Data . . .

Read More

Guidance for Industry: Conducting Clinical Trials With Decentralized Elements

The Conducting Clinical Trials With Decentralized Elements final guidance has now been . . .

Read More

Welcome FGK Clinical Research as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome FGK Clinical . . .

Read More

Welcome LINK Medical as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome LINK Medical as . . .

Read More